Work

Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation

Year: 2015

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-15-a54

Authors: Andrew Brenner, Jeffrey Infante, Manish Patel, Hendrik-Tobias Arkenau, Mark Voskoboynik, Erkut Borazanci, Gerald Falchook, L.R. Molife, Shubham Pant, Emma Dean, Lorraine Pelosof, Suzanne Jones, Chris Rubino, William McCulloch, Valentina Zhukova-Harrill, George Kemble, Marie O'Farrell, Howard A. Burris

Institutions: Sarah Cannon, Tennessee Oncology, Sarah Cannon Research Institute, HonorHealth, HealthONE, Institute of Cancer Research, University of Manchester, The Christie NHS Foundation Trust, The University of Texas Southwestern Medical Center

Language: English

Topic: Cancer, Lipids, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2397279624

Cites:

Cited by: 7

Related to: 10